JangoBio: Next Generation Hormone Replacement Therapy
“Stem cell therapies have the potential to restore hormone balance and reverse the symptoms of menopause and andropause without the negative side-effects associated with current pharmaceutical-based hormone therapies. This personalized medicine approach is a long-term fix that will enable individuals to live healthier lives, longer.” Craig S. Atwood, Ph.D., Founder and CEO of JangoBio
The loss of sex hormone balance with menopause (women) and andropause (men) leads to an array of symptoms such as hot flashes, decreased energy, weight gain, poor concentration and reduced libido that significantly impact quality of life. More troubling, the long-term consequences of this imbalance can result in several age-related diseases including Alzheimer’s disease, obesity, diabetes, heart disease and osteoporosis.
Unfortunately, there are no drugs or therapies that can completely rebalance the more than 50 sex hormones that decline as we age. Current hormone replacement therapies (HRT), like estrogen, only restore one or two hormones and come with multiple disadvantages including ongoing treatment requirements and unacceptable risks such as increased vascular disease and cancer.
JangoBio’s approach to this dilemma has been to develop a personalized, long-term solution, to completely restore sex hormones back to youthful levels. JangoBio scientists have created purpose-built, fully functional “organoids” comprised of multiple cell types that produce the array of hormones required by our bodies as we age. These patent-pending biologics are implantable and integrate into tissues to produce both sex steroids and protein hormones that are necessary for complete hormone rebalancing and optimal health and well-being.
This next generation hormone therapy is being developed through JangoMed, one of five JangoBio subsidiaries. The generation of revenues through other JangoBio subsidiaries – JangoCell (research-grade products and cell biology services), Heartland Vivarium (CRO-services) and JangoDx (diagnostic services) provides revenue streams that help speed the R&D of these biologics for the human (JangoMed) and veterinary (JangoPet) markets.
JangoMed will initially target the HRT market, which represents a $5 billion opportunity that is composed primarily of individuals that experience severe symptomology. Recent rising demand for HRT is largely being driven by the wave of symptomatic baby boomers entering their 50’s and 60’s, and patient advocacy. Expansion of our prophylactic/therapy into women and men over the age of 50 represents an additional $20 billion opportunity (at a capture rate of 10%).
By restoring hormones back to youthful levels, we can arrest the symptoms of menopause and andropause that we are all too familiar with. Our precision medicine approach has enormous implications for improving health and mitigating the diseases of aging so we can live healthier lives, longer.
For information on investing in JangoBio, contact Victor Mohoney at vmohoney@jango.bio
